Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imatinib mesylate
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Imatinib mesylate is a small molecule kinase inhibitor used to treat various types of cancer and blood conditions. It works by blocking a protein called tyrosine kinase, which helps stop cancer cells from growing and multiplying. The drug is primarily used for treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukemia (Ph+ ALL), gastrointestinal stromal tumors (GIST), and several other conditions including myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, and dermatofibrosarcoma protuberans.
- Brand names
- GleevecGlivecImkeldi
- Other names
- imatinib mesilate
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase)PDGFR (PDGFR family)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on imatinib mesylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imatinib mesylate.